In a study evaluating patients with Gleason grade group 1 (GG1) prostate cancer, the relationship between the volume of cancer at biopsy and pathological outcomes after radical prostatectomy was examined. The research focused on patients with a prostate-specific antigen (PSA) level below 20 ng/mL who underwent robot-assisted radical prostatectomy (RARP) from May 2014 to May 2023. A total of 213 patients were included, with a median age of 67 years and a median PSA level of 6.52 ng/mL at diagnosis. The study specifically looked at the percentage of positive biopsy cores (PPC), calculated as the number of positive cores divided by the total number of cores. The findings indicated a significant association between PPC and unfavorable pathological outcomes at radical prostatectomy (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.00-1.04, p=0.030). However, no significant relationship was observed between PPC and the likelihood of surgical Gleason upgrading to GG2 or higher (p=0.189). During a median follow-up period of 34 months, only 2.3% of patients experienced biochemical recurrence, with five patients reporting this outcome. The study concluded that while PPC is correlated with adverse pathology, it does not appear to influence the likelihood of upgrading in patients with GG1 prostate cancer undergoing RARP. These results underscore the importance of careful assessment of biopsy results to predict outcomes for prostate cancer patients.
10 hours ago
Top Resources for Lifelong evolving field of medical imaging, staying updated with the latest advancements and techniques is crucial for ultrasound professionals. Lifelong learning not only ensures that sonographers deliver […]
